Research progress of HGF/MET signaling pathway in EGFR-TKI resistance 
in non-small cell lung cancer

• Published in: Zhongguo fei ai za zhi Vol. 17; no. 10; pp. 755 - 759
• Main Authors: Song, Shilong, Bi, Minghong
• Format: Journal Article
• Language: Chinese
• Published: China Chinese Anti-Cancer Association Chinese Antituberculosis Association 20.10.2014; Chinese Anti-Cancer Association; Chinese Antituberculosis Association
• Subjects: Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - enzymology; Carcinoma, Non-Small-Cell Lung - pathology; Drug Resistance, Neoplasm; EGFR-TKI; Hepatocyte Growth Factor - metabolism; HGF; Humans; Kinases; Lung cancer; Lung neoplasms; Lung Neoplasms - drug therapy; Lung Neoplasms - enzymology; Lung Neoplasms - pathology; MET; Mutation; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Proto-Oncogene Proteins c-met - metabolism; Receptor, Epidermal Growth Factor - antagonists & inhibitors; Resistance; Signal Transduction - drug effects; Vascular endothelial growth factor; China
• ISSN: 1009-3419; 1999-6187
• DOI: 10.3779/j.issn.1009-3419.2014.10.08

Lung cancer is one of the most common malignant tumors of the world, and non-small cell lung cancer (NSCLC) makes up about 80%. The hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) signal pathway has pleiotropic effects on many biological processes. However, aberrant HGF/MET signal pathway activation has been observed in many tumor types, and promotes cellular proliferation and metastasis via growth factor receptors and other oncogenic receptor pathways. In recent years, aberrant HGF/MET signal pathway activation has been considered a key step of resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy. This review addresses how aberrant HGF/MET signal pathway activation being associated with drug resistance to EGFR-TKI therapy in NSCLC patients.